ImmunoGen, Inc

Published Date: 31/01/2012
Category: Emerging Technologies & Scientific Research

Research Report Decription

ImmunoGen, Inc - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360˚ view of the company.

Features:

• Detailed information on ImmunoGen, Inc required for business and competitor intelligence needs
• A study of the major internal and external factors affecting ImmunoGen, Inc in the form of a SWOT analysis
• An in-depth view of the business model of ImmunoGen, Inc including a breakdown and examination of key business segments
• Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for ImmunoGen, Inc
• Intelligence on ImmunoGen, Incnv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
• News about ImmunoGen, Inc, such as business expansion, restructuring, and contract wins
• Large number of easy-to-grasp charts and graphs that present important data and key trends

Key Questions Answered:

• Gain understanding of the ImmunoGen, Inc and the factors that influence its strategies 
• Track strategic initiatives of the company and latest corporate news and actions 
• Assess ImmunoGen, Inc as a prospective partner, vendor or supplier
• Support sales activities by understanding your customers' businesses better
• Stay up to date on ImmunoGen, Inc’s business structure, strategy and prospects

Companies Mentioned:

ImmunoGen

Paper Highlights:

ImmunoGen, a biotechnology company, develops targeted anticancer therapeutics using its tumor-activated prodrug (TAP) technology. The TAP technology uses tumor-targeting antibodies to deliver a cell-killing agent specifically to cancer cells. ImmunoGen is headquartered in Waltham, Massachusetts and employed 211 people as of June 30, 2010.  The company recorded revenues of $13.9 million during the financial year (FY) ended June 2010, a decrease of 50.2% over FY2009. The decline in revenues is primarily attributable to lower revenues from R&D support, license and milestone fees and clinical materials reimbursement. The operating loss of the company was $51.2 million during FY2010, as compared with an operating loss of $31.8 million in FY2009. The net loss was $50.9 million in FY2010, as compared with a net loss of $30.9 million in FY2009.